Progering
Alternative Name: Progestin Vaginal Ring (PVR)
Description: A progestin only 3-month vaginal ring, marketed specifically for breastfeeding women. Given its short half-life orally, it is destroyed when ingested in mother's milk and there is no impact on the infant.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Duration Type: Short-acting
Duration: 3 months
Regimen: - One ring for 3 months
- One ring for 3 months
Dose: 10 mg
Active Pharmaceutical Ingredient (API): - progestin
- progestin
Inactive material: elastomer
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Population Council, Grunenthal
Project Phase: Limited Market Availability
Development Stage: Marketed
Began discovery in: mid-1990'
Active Development: Yes
Status Details: - Progering (developed by Population Council, CONRAD, UNFPA and Silesia) has been approved for use in Bolivia, Chile, Ecuador, Guatemala, Dominican Republic, El Salvador, Panama, and Peru.
- Additional phase III study ongoing in India for submission to Government of India for approval. Additional acceptability studies ongoing in sub-Saharan Africa in preparation for introduction.
- It is under evaluation at WHO for the Essential Medicine list and prequalification program at manufacturing site.
- Progering (developed by Population Council, CONRAD, UNFPA and Silesia) has been approved for use in Bolivia, Chile, Ecuador, Guatemala, Dominican Republic, El Salvador, Panama, and Peru.
- Additional phase III study ongoing in India for submission to Government of India for approval. Additional acceptability studies ongoing in sub-Saharan Africa in preparation for introduction.
- It is under evaluation at WHO for the Essential Medicine list and prequalification program at manufacturing site.
Additional Information
References: Population Council Website: http://www.popcouncil.org/research/the-progesterone-vaginal-ring-expandi...
Population Council Website: http://www.popcouncil.org/research/the-progesterone-vaginal-ring-expandi...